Olivier Trédan

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Rucaparib Maintenance Treatment, Medicine, Recurrent Ovarian Carcinoma +7

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Breast Oncology, Endocrine-related Cancer, Medicine +14

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke et al. · Cancer Research · 2009 · 780 citations · Full text

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text